Elite in Hives

Dr. Daniel F. Soteres

Allergy and Immunology
CommonSpirit Health
Asthma & Allergy Associates, PC
2709 N Tejon St, 
Colorado Springs, CO 
Accepting New Patients
Elite in Hives
CommonSpirit Health
Asthma & Allergy Associates, PC
2709 N Tejon St, 
Colorado Springs, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Soteres is an Allergy and Immunologist in Colorado Springs, Colorado. Dr. Soteres is rated as an Elite provider by MediFind in the treatment of Hives. His top areas of expertise are Angioedema, Hereditary Angioedema, Hives, and Sinusitis. Dr. Soteres is currently accepting new patients.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 24 articles and participated in 4 clinical trials in the study of Hives.

Graduate Institution
Tulane University School Of Medicine
Residency
Tulane University School of Medicine
Specialties
Allergy and Immunology
Licenses
Allergy & Immunology in CO
Fellowships
Tulane University School of Medicine
Hospital Affiliations
Uch-Memorial Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Freedom Life
  • INSURANCE PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Asthma & Allergy Associates, PC
2709 N Tejon St, Colorado Springs, CO 80907
Call: 719-473-0872

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Longitudinal Observational Study of Patients With Chronic Disease
A Longitudinal Observational Study of Patients With Chronic Disease
Enrollment Status: Terminated
Publish Date: April 03, 2025
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Enrollment Status: Terminated
Publish Date: April 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 13 Less Clinical Trials

25 Total Publications

Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.
Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.
Journal: Clinical and translational allergy
Published: July 31, 2025
View All 25 Publications
Similar Doctors
Distinguished in Hives
Dr. James W. Fulton
Allergy and Immunology
Distinguished in Hives
Dr. James W. Fulton
Allergy and Immunology

Asthma & Allergy Associates, PC

2709 N Tejon St, 
Colorado Springs, CO 
 (0.1 miles away)
719-473-0872
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Fulton is an Allergy and Immunologist in Colorado Springs, Colorado. Dr. Fulton is rated as a Distinguished provider by MediFind in the treatment of Hives. His top areas of expertise are Allergic Conjunctivitis, Conjunctivitis (Pink Eye), Chronic Spontaneous Urticaria (CSU), and Vibratory Urticaria. Dr. Fulton is currently accepting new patients.

Distinguished in Hives
Dr. Mark A. Ebadi
Allergy and Immunology
Distinguished in Hives
Dr. Mark A. Ebadi
Allergy and Immunology

Colorado Allergy & Asthma Centers PC

125 Rampart Way, Ste 200, 
Denver, CO 
 (58.8 miles away)
720-858-7550
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Ebadi is an Allergy and Immunologist in Denver, Colorado. Dr. Ebadi is rated as a Distinguished provider by MediFind in the treatment of Hives. His top areas of expertise are Grass Allergy, Allergic Rhinitis, Sinusitis, and Hives. Dr. Ebadi is currently accepting new patients.

Advanced in Hives
Dr. Katherine S. Tsai
Allergy and Immunology
Advanced in Hives
Dr. Katherine S. Tsai
Allergy and Immunology

Colorado Allergy & Asthma Centers PC

9331 S Colorado Blvd, Ste 100, 
Highlands Ranch, CO 
 (47.1 miles away)
303-971-0311
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katherine Tsai is an Allergy and Immunologist in Highlands Ranch, Colorado. Dr. Tsai is rated as a Distinguished provider by MediFind in the treatment of Hives. Her top areas of expertise are Grass Allergy, Sinusitis, Allergic Rhinitis, and Hives. Dr. Tsai is currently accepting new patients.

VIEW MORE HIVES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Soteres's expertise for a condition
ConditionClose
  • Elite
  • Angioedema
    Dr. Soteres is
    Elite
    . Learn about Angioedema.
    See more Angioedema experts
  • Hereditary Angioedema
    Dr. Soteres is
    Elite
    . Learn about Hereditary Angioedema.
    See more Hereditary Angioedema experts
  • Hives
    Dr. Soteres is
    Elite
    . Learn about Hives.
    See more Hives experts
  • Distinguished
  • Grass Allergy
    Dr. Soteres is
    Distinguished
    . Learn about Grass Allergy.
    See more Grass Allergy experts
  • Sinusitis
    Dr. Soteres is
    Distinguished
    . Learn about Sinusitis.
    See more Sinusitis experts
  • Advanced
  • Allergic Conjunctivitis
    Dr. Soteres is
    Advanced
    . Learn about Allergic Conjunctivitis.
    See more Allergic Conjunctivitis experts
  • Allergic Rhinitis
    Dr. Soteres is
    Advanced
    . Learn about Allergic Rhinitis.
    See more Allergic Rhinitis experts
  • Asthma
    Dr. Soteres is
    Advanced
    . Learn about Asthma.
    See more Asthma experts
  • Complement Component 2 Deficiency
    Dr. Soteres is
    Advanced
    . Learn about Complement Component 2 Deficiency.
    See more Complement Component 2 Deficiency experts
  • Eosinophilic Esophagitis
    Dr. Soteres is
    Advanced
    . Learn about Eosinophilic Esophagitis.
    See more Eosinophilic Esophagitis experts
  • Hyperphenylalaninemia Due to Dehydratase Deficiency
    Dr. Soteres is
    Advanced
    . Learn about Hyperphenylalaninemia Due to Dehydratase Deficiency.
    See more Hyperphenylalaninemia Due to Dehydratase Deficiency experts
View All 8 Advanced Conditions
  • Experienced
  • Asthma in Children
    Dr. Soteres is
    Experienced
    . Learn about Asthma in Children.
    See more Asthma in Children experts
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    Dr. Soteres is
    Experienced
    . Learn about Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
    See more Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) experts
  • Chronic Spontaneous Urticaria (CSU)
    Dr. Soteres is
    Experienced
    . Learn about Chronic Spontaneous Urticaria (CSU).
    See more Chronic Spontaneous Urticaria (CSU) experts
  • Common Variable Immune Deficiency
    Dr. Soteres is
    Experienced
    . Learn about Common Variable Immune Deficiency.
    See more Common Variable Immune Deficiency experts
  • Conjunctivitis (Pink Eye)
    Dr. Soteres is
    Experienced
    . Learn about Conjunctivitis (Pink Eye).
    See more Conjunctivitis (Pink Eye) experts
  • Food Allergy
    Dr. Soteres is
    Experienced
    . Learn about Food Allergy.
    See more Food Allergy experts
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.